Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Trop Med Hyg ; 61(2): 350-4, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10463693

ABSTRACT

Between November 1993 and March 1994, a cluster 6 pediatric patients with acute febrile illnesses associated with rashes was identified in Jujuy Province, Argentina. Immunohistochemical staining of tissues confirmed spotted fever group rickettsial infection in a patient with fatal disease, and testing of serum of a patient convalescing from the illness by using an indirect immunofluorescence assay (IFA) demonstrated antibodies reactive with spotted fever group rickettsiae. A serosurvey was conducted among 16 households in proximity to the index case. Of 105 healthy subjects evaluated by IFA, 19 (18%) demonstrated antibodies reactive with rickettsiae or ehrlichiae: 4 had antibodies reactive with Rickettsia rickettsii, 15 with Ehrlichia chaffeensis, and 1 with R. typhi. Amblyomma cajennense, a known vector of R. rickettsii in South America, was collected from pets and horses in the area. These results are the first to document rickettsial spotted fever and ehrlichial infections in Argentina.


Subject(s)
Ehrlichia chaffeensis/isolation & purification , Ehrlichiosis/epidemiology , Rickettsia rickettsii/isolation & purification , Rocky Mountain Spotted Fever/epidemiology , Adolescent , Adult , Antibodies, Bacterial/blood , Argentina/epidemiology , Child , Child, Preschool , Ehrlichia chaffeensis/immunology , Fatal Outcome , Female , Fluorescent Antibody Technique , Humans , Immunoenzyme Techniques , Male , Rickettsia rickettsii/immunology , Rocky Mountain Spotted Fever/physiopathology , Seroepidemiologic Studies
2.
Trans R Soc Trop Med Hyg ; 88(1): 95-7, 1994.
Article in English | MEDLINE | ID: mdl-8154019

ABSTRACT

In an open trial, longer courses of pentavalent antimonials (Sbv) at sub-optimal doses (10 mg/kg body weight), in association with recombinant human interferon-gamma (IFN-gamma) (100 micrograms/m2 of body surface area) were administered, by daily intramuscular injections, to 13 patients with diagnoses of cutaneous or mucocutaneous leishmaniasis unresponsive to Sbv. Four patients presented with large skin ulcers, and 9 had mucosal involvement as the main manifestation, the latter affecting the nose (3 cases), nose and septum (2 cases), nose and oral cavity (1 case), and nose, pharynx and larynx (3 cases). Except for one case with severe involvement of the upper respiratory tract, the lesions were fully resolved by the end of therapy (mean duration 40 +/- 12 [SD] d, range 30-60 d) in the 11 patients who completed therapy. The main side effects were headache and fever (7 cases), together with leucopenia and eosinophilia (4 cases). It is concluded that combined administration of low doses of Sbv plus IFN-gamma may provide a novel therapeutic approach for the treatment of antimony-resistant cutaneous or mucocutaneous leishmaniasis. The possible mechanisms by which IFN-gamma contributes to resolution of the disease are discussed.


Subject(s)
Antimony/therapeutic use , Interferon-gamma/therapeutic use , Leishmaniasis, Cutaneous/therapy , Adolescent , Adult , Antimony/adverse effects , Combined Modality Therapy , Drug Resistance , Female , Follow-Up Studies , Humans , Interferon-gamma/adverse effects , Leishmaniasis, Mucocutaneous/therapy , Male , Middle Aged , Recombinant Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...